NEW KTI/CTI PROJECT FOR ONCOLOGY TARGETS

Memo Therapeutics AG was awarded a new CTI grant

 

 

Memo Therapeutics AG has secured a third CTI project entitled “Novel cell-based immunization technology and functional validation of resulting antibodies” which is intended to complement its MemoMAB^TM platform with a focus for the discovery of difficult targets  such as GPCRs (G Protein-Coupled Receptors). The novel immunization method will be validated through the discovery of antibody portfolios against two novel oncology targets.

For this project Memo Therapeutics AG collaborates with ZHAW and two translational oncology groups at Universities of Basel and Bern.